Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Melanoma exhibits a high mutation rate, driven by oncogenic mutations contributing to its aggressive nature.
• Advanced genomic technologies identify mutational signatures and pathway alterations crucial for melanoma development.
• Targeting specific molecular alterations has improved outcomes in various cancers, including melanoma.

Purpose of the Study:

• To review potential druggable mutations in melanoma.
• To discuss novel, individualized treatment strategies targeting non-BRAF mutations.

Main Methods:

• Literature review of current research on melanoma mutations and targeted therapies.
• Analysis of distinct mutational signatures and downstream alterations in key cancer pathways.
• Evaluation of ongoing clinical research for novel individualized treatment approaches.

Main Results:

• BRAF and MEK inhibitors are the only approved targeted therapies for BRAF-mutant melanoma.
• Despite high mutation rates, melanoma has fewer approved precision drugs compared to other cancers.
• Numerous potential druggable mutations beyond BRAF are being investigated.

Conclusions:

• Further research is essential to develop effective therapeutics for melanoma.
• Targeting non-BRAF mutations represents a promising avenue for novel melanoma treatments.
• Individualized treatment approaches hold significant potential for improving melanoma patient outcomes.